Biomarkers and Molecular Mechanism Study of Hepatocellular Carcinoma After Radical Resection and Conversion Therapy

Fudan University

Status: Enrolling

Conditions: Hepatocellular Carcinoma

Treatments: Diagnostic Test: Plasma proteomic analysis; Diagnostic Test: ctDNA monitoring

Study type: Observational

Funder types: Other

Identifiers

NCT06382103

B2024-108R

Details and patient eligibility

About

Blood samples will be tested to identify circulating tumor DNA and plasma protein levels to potentially improve prediction of long term prognosis and guide treatment options of patients with hepatocellular carcinoma underwent surgical resection.

Enrollment: 240 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with a first diagnosis of HCC.
• Patients with HCC who are to undergo surgical treatment, with or without neoadjuvant therapy.
• Ability to obtain tissue sample for ctDNA analysis and detectable baseline ctDNA level.

Exclusion criteria

• Patients with secondary liver cancer, or intrahepatic cholangiocarcinoma.
• Any other concurrent malignancy.
• History of organ transplant or hepatic encephalopathy.